Trial Profile
SURE CANADA: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once Weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE CANADA
- Sponsors Novo Nordisk
- 06 Oct 2023 Results of pooled post hoc analysis from SURE programme: Canada, Denmark/Sweden, France, Germany, Italy, the Netherlands, Switzerland, Spain and the UK psafety of once-weekly (OW) semaglutide prescribed to adults with type 2 diabetes (T2D) in routine clinical practice presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 01 Oct 2021 Primary endpoint (Change in Glycated Haemoglobin A1c (HbA1c)) has been met, as per results published in the Diabetes, Obesity and Metabolism.
- 01 Oct 2021 Results assessing efficacy and safety of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice, published in the Diabetes, Obesity and Metabolism.